|1.||Gaestel, Matthias: 22 articles (12/2015 - 05/2002)|
|2.||Noguchi, Koichi: 21 articles (02/2015 - 05/2003)|
|3.||Wang, Wei: 20 articles (10/2015 - 02/2003)|
|4.||Li, Yan: 19 articles (01/2016 - 10/2003)|
|5.||Dong, Zigang: 19 articles (02/2015 - 01/2003)|
|6.||Alessi, Dario R: 19 articles (06/2013 - 03/2002)|
|7.||Herlyn, Meenhard: 18 articles (04/2015 - 01/2002)|
|8.||Bode, Ann M: 18 articles (02/2015 - 01/2003)|
|9.||Chung, Jing-Gung: 17 articles (09/2015 - 03/2010)|
|10.||Yamanaka, Hiroki: 17 articles (02/2015 - 05/2003)|
07/01/2010 - "Inhibition of various protein kinases has already been investigated in many pre-clinical and clinical trials targeting all stages of signal transduction, demonstrating promising results in cancer therapy. "
01/02/2015 - "We sought an improved understanding of protein kinase chaperoning by CDC37 in cancer cells. "
01/28/2012 - "Mitogen activated protein kinase phosphatase-1 (MKP-1) protein levels are elevated in various tumors and are negatively correlated with efficacy of chemo- or radio-therapy. "
01/01/2015 - "The Rho/ROCK pathway is involved in numerous pivotal cellular processes that have made it an area of intense study in cancer medicine, however, Rho-associated coiled-coil containing protein kinase (ROCK) inhibitors are yet to make an appearance in the clinical cancer setting. "
01/01/2014 - "In this study, we provide a detailed structural classification and analysis of functional dynamics for members of protein kinase families that are known to harbor cancer mutations. "
|2.||Melanoma (Melanoma, Malignant)
01/01/2014 - "Combining selective BRAF and MEK inhibition, such as the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib, has been shown to improve the response rate and progression-free survival in patients with advanced melanoma while significantly alleviating the paradoxical activation of mitogen-activated protein kinase. "
06/01/2014 - "However, improved understanding of melanoma driver mutations, particularly those involving the mitogen-activated protein kinase pathway, has led to the development of targeted therapies that are effective in this previously treatment-refractory disease. "
01/01/2015 - "New therapies, such as mitogen-activated protein kinase (MAPK) pathway inhibitors as well as other signaling pathway inhibitors, are being tested in patients with metastatic melanoma either as monotherapy or in combination, and all have yielded promising results. "
05/01/2015 - "Recovery of mitogen activated protein kinase (MAPK) or activation of alternative pathways, such as the PI3K/AKT/mTOR, are involved in acquired resistance to BRAF inhibitors which represent the first-line treatment of BRAF-mutated metastatic melanoma. "
06/01/2013 - "These recent advances have been facilitated by an improved understanding of the driving genetic aberrations of melanoma, particularly mutations in the mitogen-activated protein kinase (MAPK) pathway. "
11/15/2002 - "The purpose of this study was to determine whether the mitogen-activated protein kinase (MAPK) signaling pathway in the retina plays a neuroprotective role against ischemia- reperfusion injury. "
03/01/2002 - "Several studies have implicated the mitogen-activated protein kinase (MAPK) signal pathway in non-hepatic organ ischemia-reperfusion injury. "
08/01/2015 - "Activation of PKCβ (protein kinase Cβ) plays a critical role in myocardial I/R (ischaemia/reperfusion) injury in non-diabetic rodents. "
03/01/2015 - "The mechanism through which the protein kinase Akt (also called PKB), protects the heart against acute ischaemia-reperfusion injury (IRI) is not clear. "
01/01/2015 - "The protein kinase 2 inhibitor tetrabromobenzotriazole protects against renal ischemia reperfusion injury."
01/01/2013 - "The present study was designed to examine if the extracellular regulated protein kinases 1/2 (ERK1/2) signaling pathway mediated protection against cardiac dysfunction after SO2 preconditioning in isolated rat hearts subjected to ischemia/reperfusion (I/R). "
06/01/2013 - "Activation of protein kinase C∊ (PKC∊) confers protection against neuronal ischemia/reperfusion. "
06/01/2010 - "In this study we investigated whether the effect of 17-beta-estradiol on ischemia-induced mitochondrial dysfunctions and apoptosis is mediated by activation of signaling protein kinases in a Langendorff-perfused rat heart model of stop-flow ischemia. "
11/01/2009 - "Previous studies have shown that KA receptor subunit GluR6 mediated c-Jun N-terminal protein kinase (JNK) signaling is involved in global ischemia injury. "
06/01/2003 - "The present study was to detect the effect of bFGF on the activities of mitogen-activated protein kinase (MAPK) signaling pathway in rat intestine after I/R injury, and to investigate the protective mechanisms of bFGF on intestinal ischemia injury. "
07/01/2012 - "The aim of the current study was to examine whether these protective effects were due to attenuation of mitogen activated protein kinase (MAPK) signaling pathways, which are known to promote inflammation and apoptosis. "
01/01/2015 - "This study aims to investigate the role of mitogen-activated protein kinase phosphatase 2 (MKP-2) in inflammation during macrophage-adipocyte interaction. "
01/01/2014 - "The aim of this study was to investigate the role of cGMP-dependent protein kinase (PKG) in mediating the anticontractile function of perivascular adipose tissue (PVAT) and whether its activation can rescue PVAT activity which is lost in an experimental model of inflammation. "
12/01/2013 - "The aim of this study was to clarify to which extent RAGE and its signaling pathways such as the so called mitogen-activated protein kinase (MAPK) pathways can contribute to the perpetuation of inflammation in the aging organism. "
08/01/2013 - "The present study aimed to investigate the role of the p38 mitogen-activated protein kinase (MAPK)/nuclear factor-κB (NF-κB) pathway in DOX-induced inflammation and cytotoxicity. "
|2.||Adenosine Monophosphate (AMP)
|5.||Protein Kinases (Protein Kinase)
|6.||NF-kappa B (NF-kB)
|10.||Proto-Oncogene Proteins c-akt (Protein Kinase B)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|5.||Transplantation (Transplant Recipients)